跳至主要内容

What is a PDX mouse model and what are PDX models used for?

In this article, I will introduce you to the PDX model, its history and development, advantages over traditional cancer models, applications in cancer treatment and drug development, success stories, challenges and limitations, future prospects, collaboration and partnerships, and my conclusion.

Introduction to the PDX model

The PDX model, also known as patient-derived xenograft, is a preclinical cancer model that involves transplanting cancer cells directly from a patient's tumor into an immunodeficient mouse. The mouse is then used to study the tumor's biology, response to treatment, and drug efficacy. The PDX model is considered a more accurate representation of human cancer than traditional cancer models, such as cell lines and mouse models, because it retains the heterogeneity and complexity of the patient's tumor. Now, Medicilon have the PDX models covering colon cancer, lung cancer, gastric cancer, breast cancer, liver cancer, pancreas cancer.



History and development of the PDX model

The first PDX model was developed in the early 1990s by transplanting human leukemia cells into immunodeficient mice. Since then, the PDX model has been adapted to various types of cancer, including breast, lung, prostate, and colon cancer. The PDX model has also been used to study cancer metastasis and drug resistance. The development of the PDX model was driven by the need for better preclinical models that accurately predict clinical outcomes.

Advantages of the PDX model over traditional cancer models

The PDX model has several advantages over traditional cancer models. Firstly, it retains the heterogeneity and complexity of the patient's tumor, which is crucial for studying cancer biology and drug response. Secondly, it allows for the testing of multiple drugs simultaneously, which can accelerate drug development and reduce costs. Thirdly, it can predict clinical outcomes more accurately than traditional cancer models, which can reduce the failure rate of clinical trials. Lastly, it can be used to study rare and aggressive cancers that are difficult to model in vitro.

How the PDX model works

The PDX model involves several steps. Firstly, a patient's tumor is obtained through biopsy or surgery. Secondly, the tumor is fragmented and transplanted into an immunodeficient mouse. Thirdly, the tumor is allowed to grow in the mouse until it reaches a certain size. Fourthly, the mouse is treated with different drugs, either alone or in combination, to test their efficacy. Lastly, the tumor is harvested and analyzed to study its biology and drug response.

Applications of the PDX model in cancer treatment and drug development

The PDX model has several applications in cancer treatment and drug development. Firstly, it can be used to identify new drug targets and test the efficacy of novel drugs. Secondly, it can be used to study drug resistance and develop strategies to overcome it. Thirdly, it can be used to personalize cancer treatment by selecting the most effective drugs for individual patients. Fourthly, it can be used to study the biology of cancer metastasis and develop therapies to prevent it.

Success stories of the PDX model in cancer research

The PDX model has already shown promising results in cancer research. For example, a PDX model of triple-negative breast cancer (TNBC) was used to identify a new drug target, CDK7, that was found to be overexpressed in TNBC patients. The PDX model was also used to test the efficacy of a new drug, THZ1, that targets CDK7, and found to be effective in reducing tumor growth. Another success story is the use of PDX models to study drug resistance in non-small cell lung cancer (NSCLC) and develop combination therapies that overcome resistance.

Challenges and limitations of the PDX model

The PDX model also has several challenges and limitations. Firstly, it is time-consuming and expensive to develop and maintain PDX models. Secondly, the engraftment rate of patient tumors into mice can vary and depend on several factors, such as the mouse strain and the tumor type. Thirdly, the PDX model may not fully represent the complexity of the patient's tumor microenvironment, which can affect drug response. Lastly, the ethical implications of using animals in cancer research need to be considered.

Future of the PDX model in cancer research

Despite the challenges and limitations, the PDX model has a bright future in cancer research. Advances in technology, such as CRISPR/Cas9 gene editing and organoid culture, can enhance the accuracy and efficiency of PDX models. Collaboration and partnerships between academia, industry, and patient advocacy groups can also accelerate the development and application of PDX models. The PDX model can also be used to study the effects of immunotherapy and combination therapies, which are promising approaches in cancer treatment.

Collaboration and partnerships in the PDX model

Collaboration and partnerships are crucial for the success of the PDX model. Academia can provide expertise in cancer biology and drug development, while industry can provide resources and funding for clinical trials. Patient advocacy groups can provide valuable input on patient needs and preferences. The PDX model can also benefit from international collaboration and standardization of protocols and data sharing. The ultimate goal of collaboration and partnerships is to translate PDX model research into clinical applications that benefit patients.

Conclusion

In conclusion, the PDX model is an innovative preclinical cancer model that has the potential to revolutionize cancer treatment and drug development. The PDX model retains the heterogeneity and complexity of the patient's tumor, allows for the testing of multiple drugs simultaneously, predicts clinical outcomes more accurately, and can be used to study rare and aggressive cancers. The PDX model has already shown promising results in identifying new drug targets, overcoming drug resistance, and personalizing cancer treatment. However, the PDX model also has challenges and limitations that need to be addressed. Collaboration and partnerships are crucial for the success of the PDX model in translating research into clinical applications that benefit patients.

Medicilon's PDX Model

Now, Medicilon have the PDX models covering colon cancer, lung cancer, gastric cancer, breast cancer, liver cancer, pancreas cancer. Our research on PDX model includes molecular level genotyping and pharmacological efficacy evaluation service of orthotopic model, promising great prediction for clinical efficacy research.

 

标签：

评论

发表评论

此博客中的热门博文

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

  On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration.  The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages      Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies,  ADCs ,  mRNA vaccines ,  small nucleic acid drugs ,  PROTAC , and  CGT technical service platform  that have helped 421 INDs obtain clinical approval.  It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...
发表评论
阅读全文

A Nickel-Catalyzed Reductive Alkylation of Aryl Bromides and Chlorides for Sp3-Sp2 Bond Formation

  In 2012, a nickel-catalyzed reductive alkylation method of aryl bromides and chlorides was reported. Under the optimized conditions, a variety of aryl and vinyl bromides as well as active aryl chloride can be reductively coupled with alkyl bromides in high yields. The protocols were highly functional-group tolerant and the reactions were not air or moisture sensitive. The reaction showed different chemoselectivity than conventional cross-coupling reactions. Substrates bearing both anelectrophilic and nucleophilic carbon resulted in selective coupling at the electrophilic carbon (R-X) and no reaction occurred at the nucleophilic carbon (R-[M]). The 2010 Nobel Prize in Chemistry was awarded for the Pd-catalyzed cross-coupling, and in the past decade the progress in cross-coupling has not only had a significant impact on academic research but has also influenced the industrial synthetic application. The transition-metal-catalyzed union of nucleophilic organo-boronic acids with elect...
发表评论
阅读全文

What is Toxicokinetics?

Toxicokinetics  is essentially the study of “how a substance gets into the body and what happens to it in the body”. Four processes are involved in toxicokinetics. The study of the kinetics (movement) of chemicals was originally conducted with pharmaceuticals and thus the term pharmacokinetics became commonly used. In addition, toxicology studies were initially conducted with drugs. However, the science of toxicology has evolved to include environmental and occupational chemicals as well as drugs. Toxicokinetics is thus the appropriate term for the study of the kinetics of all toxic substances. Frequently the terms  toxicokinetics ,  pharmacokinetics , or disposition may be found in the literature to have the same meaning. Disposition is often used in place of toxicokinetics to describe the time-course of movement of chemicals through the body (that is, how does the body dispose of a xenobiotic?). The disposition of a toxicant along with its’ biological reactivi...
发表评论
阅读全文